Recombinant Humanised Igg1 Kappa Anti-Oncostatin M Monoclonal Antibody Gsk2330811
Systemic Sclerosis
GlaxoSmithKlinemonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
25 Active assets in the Systemic Sclerosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Royal Brompton & Harefield NHS Foundation Trust | Phase 2/3 | BB |
Iloprost National Center for Research Resources (NCRR) | Phase 3 | BB |
Bosentan Actelion | Phase 3 | B |
Rituximab Royal Brompton & Harefield NHS Foundation Trust | Phase 2/3 | B |
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Fred Hutchinson Cancer Center | Phase 2 | B |
View all 41 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →